Recent advances in therapy for multiple sclerosis (MS) have centred on the use of the disease-modifying drugs glatiramer acetate (GA) and interferon (IFN) β. Several large-scale clinical trials have been carried out on the use of these compounds, but there have been few studies that have directly compared their efficacy in MS. Furthermore, there has been controversy and confusion over the IFN β therapy regimen that will achieve the best possible clinical outcome for MS patients. This review focuses principally on clinical trials of IFN β-1a, where data that allow direct comparison of different treatment regimens are now available. Current data indicate that IFN β, and in particular IFN β-1a, has important advantages over GA in the treatment of relapsing-remitting MS (RRMS). Additionally, IFN β-1a (Rebif®, Serono), 44 pg administered subcutaneously (s.c.) three times weekly (t.i.w.), is significantly more effective than IFN β-1a (Avonex®, Biogen), 30 μg administered intramuscularly once weekly. For optimal management of RRMS, treatment with IFN ¢-1a, 44 μg s.c. t.i.w., should begin as early as possible after diagnosis

Interferon beta and multiple sclerosis: look at the evidence

PATTI, Francesco;
2002-01-01

Abstract

Recent advances in therapy for multiple sclerosis (MS) have centred on the use of the disease-modifying drugs glatiramer acetate (GA) and interferon (IFN) β. Several large-scale clinical trials have been carried out on the use of these compounds, but there have been few studies that have directly compared their efficacy in MS. Furthermore, there has been controversy and confusion over the IFN β therapy regimen that will achieve the best possible clinical outcome for MS patients. This review focuses principally on clinical trials of IFN β-1a, where data that allow direct comparison of different treatment regimens are now available. Current data indicate that IFN β, and in particular IFN β-1a, has important advantages over GA in the treatment of relapsing-remitting MS (RRMS). Additionally, IFN β-1a (Rebif®, Serono), 44 pg administered subcutaneously (s.c.) three times weekly (t.i.w.), is significantly more effective than IFN β-1a (Avonex®, Biogen), 30 μg administered intramuscularly once weekly. For optimal management of RRMS, treatment with IFN ¢-1a, 44 μg s.c. t.i.w., should begin as early as possible after diagnosis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/2496
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact